Trial 3P-23-6


A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Vaccine
Randomized: No
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Diana Hanna, M.D.
Other Trial Staff:  Charlean Ketchens, Coordinator, Mary Ordaz, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Niranjan Bhatt, D.M., Rabia Rehman, Coordinator, Angela Smith Bryant, Coordinator, Young-Wook Kim, Coordinator, Syed Husein, D.M., Diane Chun, Coordinator, Janet Luong, Coordinator, Liza Pizarro, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.